<?xml version='1.0' encoding='utf-8'?>
<document id="26439054"><sentence text="Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report."><entity charOffset="28-39" id="DDI-PubMed.26439054.s1.e0" text="daclatasvir" /><entity charOffset="44-55" id="DDI-PubMed.26439054.s1.e1" text="asunaprevir" /><pair ddi="false" e1="DDI-PubMed.26439054.s1.e0" e2="DDI-PubMed.26439054.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26439054.s1.e0" e2="DDI-PubMed.26439054.s1.e1" /></sentence><sentence text="We previously reported our data on telaprevir or simeprevir used in combination with pegylated interferon (PEG IFN) and ribavirin (RBV) for the treatment of recurrent hepatitis C virus (HCV) genotype 1 infection after liver transplantation (LT)"><entity charOffset="35-45" id="DDI-PubMed.26439054.s2.e0" text="telaprevir" /><entity charOffset="49-59" id="DDI-PubMed.26439054.s2.e1" text="simeprevir" /><entity charOffset="120-129" id="DDI-PubMed.26439054.s2.e2" text="ribavirin" /><entity charOffset="131-134" id="DDI-PubMed.26439054.s2.e3" text="RBV" /><pair ddi="false" e1="DDI-PubMed.26439054.s2.e0" e2="DDI-PubMed.26439054.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26439054.s2.e0" e2="DDI-PubMed.26439054.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26439054.s2.e0" e2="DDI-PubMed.26439054.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26439054.s2.e0" e2="DDI-PubMed.26439054.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26439054.s2.e1" e2="DDI-PubMed.26439054.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26439054.s2.e1" e2="DDI-PubMed.26439054.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26439054.s2.e1" e2="DDI-PubMed.26439054.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26439054.s2.e2" e2="DDI-PubMed.26439054.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26439054.s2.e2" e2="DDI-PubMed.26439054.s2.e3" /></sentence><sentence text=" Here, we report three patients who achieved viral responses with no effect on the blood concentrations of immunosuppressive agents following daclatasvir and asunaprevir treatment"><entity charOffset="142-153" id="DDI-PubMed.26439054.s3.e0" text="daclatasvir" /><entity charOffset="158-169" id="DDI-PubMed.26439054.s3.e1" text="asunaprevir" /><pair ddi="false" e1="DDI-PubMed.26439054.s3.e0" e2="DDI-PubMed.26439054.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26439054.s3.e0" e2="DDI-PubMed.26439054.s3.e1" /></sentence><sentence text=" The first patient was a 57-year-old man with HCV-related liver cirrhosis who failed to respond to PEG IFN/RBV after living donor LT"><entity charOffset="107-117" id="DDI-PubMed.26439054.s4.e0" text="RBV" /></sentence><sentence text=" He had been treated with 1 mg/day of tacrolimus"><entity charOffset="38-48" id="DDI-PubMed.26439054.s5.e0" text="tacrolimus" /></sentence><sentence text=" The second was a 63-year-old man with HCV-related liver cirrhosis and hepatocellular carcinoma who failed to respond to PEG IFN/RBV after living donor LT"><entity charOffset="129-138" id="DDI-PubMed.26439054.s6.e0" text="RBV" /></sentence><sentence text=" He had been treated with 1 mg/day of tacrolimus"><entity charOffset="38-48" id="DDI-PubMed.26439054.s7.e0" text="tacrolimus" /></sentence><sentence text=" The third was a 61-year-old man with HCV-related liver cirrhosis" /><sentence text=" He had been treated with mycophenolate mofetil (MMF)"><entity charOffset="26-47" id="DDI-PubMed.26439054.s9.e0" text="mycophenolate mofetil" /><entity charOffset="49-52" id="DDI-PubMed.26439054.s9.e1" text="MMF" /><pair ddi="false" e1="DDI-PubMed.26439054.s9.e0" e2="DDI-PubMed.26439054.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26439054.s9.e0" e2="DDI-PubMed.26439054.s9.e1" /></sentence><sentence text=" Serum HCV RNA became undetectable by TaqMan polymerase chain reaction test after 4 weeks of daclatasvir and asunaprevir treatment in all patients, and no remarkable fluctuations in blood concentration were observed either in tacrolimus or in MMF during 24 weeks of therapy"><entity charOffset="93-104" id="DDI-PubMed.26439054.s10.e0" text="daclatasvir" /><entity charOffset="109-120" id="DDI-PubMed.26439054.s10.e1" text="asunaprevir" /><entity charOffset="226-236" id="DDI-PubMed.26439054.s10.e2" text="tacrolimus" /><entity charOffset="243-252" id="DDI-PubMed.26439054.s10.e3" text="MMF" /><pair ddi="false" e1="DDI-PubMed.26439054.s10.e0" e2="DDI-PubMed.26439054.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26439054.s10.e0" e2="DDI-PubMed.26439054.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26439054.s10.e0" e2="DDI-PubMed.26439054.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26439054.s10.e0" e2="DDI-PubMed.26439054.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26439054.s10.e1" e2="DDI-PubMed.26439054.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26439054.s10.e1" e2="DDI-PubMed.26439054.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26439054.s10.e1" e2="DDI-PubMed.26439054.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26439054.s10.e2" e2="DDI-PubMed.26439054.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26439054.s10.e2" e2="DDI-PubMed.26439054.s10.e3" /></sentence><sentence text=" No adverse events were observed, and all patients received the full dose of daclatasvir and asunaprevir over 24 weeks"><entity charOffset="77-88" id="DDI-PubMed.26439054.s11.e0" text="daclatasvir" /><entity charOffset="93-104" id="DDI-PubMed.26439054.s11.e1" text="asunaprevir" /><pair ddi="false" e1="DDI-PubMed.26439054.s11.e0" e2="DDI-PubMed.26439054.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26439054.s11.e0" e2="DDI-PubMed.26439054.s11.e1" /></sentence><sentence text=" Serum HCV RNA remained negative at 12 weeks after the end of treatment in all patients" /><sentence text=" The daclatasvir and asunaprevir treatment showed a remarkable viral response with little effect on blood levels of immunosuppressive agents for recurrent HCV genotype 1 infection after LT"><entity charOffset="5-16" id="DDI-PubMed.26439054.s13.e0" text="daclatasvir" /><entity charOffset="21-32" id="DDI-PubMed.26439054.s13.e1" text="asunaprevir" /><pair ddi="false" e1="DDI-PubMed.26439054.s13.e0" e2="DDI-PubMed.26439054.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26439054.s13.e0" e2="DDI-PubMed.26439054.s13.e1" /></sentence><sentence text=" " /></document>